Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Aspirin  COVID-19 treatment studies for Aspirin  C19 studies: Aspirin  Aspirin   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 28% Improvement Relative Risk Mortality 62% Time to viral- 10% Time to viral- (b) 15% Merzon et al. Aspirin for COVID-19 Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? Retrospective 10,477 patients in Israel Fewer cases (p=0.041) and faster viral clearance (p=0.045) Merzon et al., The FEBS J., doi:10.1111/febs.15784 Favors aspirin Favors control
The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection
Merzon et al., The FEBS Journal, doi:10.1111/febs.15784
Merzon et al., The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of.., The FEBS Journal, doi:10.1111/febs.15784
Feb 2021   Source   PDF  
  All Studies   Meta
Retrospective 10,477 patients in Israel, showing lower risk of COVID-19 cases with existing aspiring use.
risk of case, 27.6% lower, RR 0.72, p = 0.04, treatment 73 of 1,621 (4.5%), control 589 of 8,856 (6.7%), NNT 47, adjusted per study, odds ratio converted to relative risk.
risk of death, 62.4% lower, RR 0.38, p = 0.51, treatment 1 of 21 (4.8%), control 6 of 91 (6.6%), adjusted per study, odds ratio converted to relative risk.
time to viral-, 9.6% lower, relative time 0.90, p = 0.045, treatment 73, control 589, time to 2nd negative test.
time to viral-, 14.8% lower, relative time 0.85, p = 0.005, treatment 73, control 589, time to 1st negative test.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Merzon et al., 23 Feb 2021, retrospective, Israel, peer-reviewed, 8 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperAspirinAll
Abstract: The use of aspirin for primary prevention of cardiovascular disease is associated with a lower likelihood of COVID-19 infection Eugene Merzon1,2, Ilan Green1,2, Shlomo Vinker1,2, Avivit Golan-Cohen1,2, Alessandro Gorohovski4, Eva Avramovich1,3, Milana Frenkel-Morgenstern4 and Eli Magen1,5 1 Leumit Health Services, Tel-Aviv, Israel 2 Department of Family Medicine, Sackler Faculty of Medicine, Tel-Aviv University, Israel 3 Department of Management, Bar-Ilan University, Safed, Israel 4 Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel 5 Medicine C Department, Clinical Immunology and Allergy Division, Barzilai University Medical Center, Ben-Gurion University of the Negev, Ashkelon, Israel Keywords aspirin; COVID-19; disease likelihood; Israeli cohort Correspondence M. Frenkel-Morgenstern, Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel Tel: +972722644901 E-mail: Eugene Merzon and Ilan Green contributed equally to this article (Received 12 November 2020, revised 18 January 2021, accepted 22 February 2021) doi:10.1111/febs.15784 Acetylsalicylic acid (aspirin) is commonly used for primary and secondary prevention of cardiovascular diseases. Aspirin use is associated with better outcomes among COVID-19 positive patients. We hypothesized that the aspirin use for primary cardiovascular disease prevention might have a protective effect on COVID-19 susceptibility and disease duration. We conducted a retrospective population-based cross-sectional study, utilizing data from the Leumit Health Services database. The proportion of patients treated with aspirin was significantly lower among the COVID-19-positive group, as compared to the COVID-19-negative group [73 (11.03%) vs. 1548 (15.77%); P = 0.001]. Aspirin use was associated with lower likelihood of COVID-19 infection, as compared to nonusers (adjusted OR 0.71 (95% CI, 0.52 to 0.99; P = 0.041). Aspirin users were older (68.06  12.79 vs. 56.63  12.28 years of age; P < 0.001), presented a lower BMI (28.77  5.4 vs. 30.37  4.55; P < 0.0189), and showed higher prevalence of hypertension (56, 76.71%), diabetes (47, 64.38%), and COPD (11, 15.07%) than the aspirin nonusers (151, 25.64%, P < 0.001; 130, 22.07%, P < 0.001; and 43, 7.3%, P = 0.023, respectively). Moreover, COVID-19 disease duration (considered as the time between the first positive and second negative COVID-19 RT–PCR test results) among aspirin users was significantly shorter, as compared to aspirin nonusers (19.8  7.8 vs. 21.9  7.9 P = 0.045). Among hospitalized COVID-positive patients, a higher proportion of surviving subjects were treated with aspirin (20, 19.05%), as opposed to 1 dead subject (14.29%), although this difference was not significant (P = 0.449). In conclusion, we observed an inverse association between the likelihood of COVID-19 infection, disease duration and mortality, and aspirin use for primary prevention. Abbreviations COVID-19, coronavirus SARS-CoV-2; CVD, cardiovascular disease; LHS, Leumit Health Services; SES, socioeconomic status; STING, stimulator of interferon genes. The FEBS Journal 288 (2021) 5179–5189 ª 2021 Federation of European Biochemical Societies 5179 E. Merzon et al. The use of aspirin lowers COVID-19 susceptibility
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop